20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
The analysis of a single cancer driver has a very low value in terms of prevention, and none in terms of prediction. The added value of the BIOSCIENCE GENOMICS proposal is the integrated analysis of at least 4 to 5 different cancer drivers, which will enable very sophisticated profiling based on multi-layer, multi-target and multi-biomarker data. Currently, BIOSCIENCE GENOMICS is the first and only company in the world to introduce the Cancer Driver Interception model as a valuable alternative to Cancer Early Detection in colorectal cancer prevention. Intercepting and treating pathophysiological conditions, which are drivers of tumor development, improve the outcomes in the battle against cancer, a disease that becomes more complex and difficult to eradicate as it progresses. The combined analysis of multiple cancer drivers allows the most detailed profiling ever offered to healthy people aiming at reducing their cancer risks.
